Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
A man who was blasted three times during the Tunisian beach massacre said he shielded his fiancee and told her: "I'm going to die."
SNP calls on the Prime Minister to "think again" on proposals to give English MPs a veto over legislation which affects only England.
Heavy showers set to spread into western areas tomorrow.